Table 2.
Comparison between diffuse and partial involvement of lymph nodes. The percentage is exhibited ignoring missing data. Descriptive statistics and one-variable analysis- outcomes data.
| Involvement degree | Partial positivity N= 40 (51.9%) | Diffuse positivity N=37 (48.1%) | p-value |
|---|---|---|---|
| Steroid treatment after a year, n (%) | 18 (45.0%) | 7 (18.9%) | 0.015 |
| Number of hospitalizations over a year (mean ±SD) | 0.53 (±1.15) | 0.27 (±0.65) | 0.447 |
| FEV1 a year after biopsy (mean ±SD) | 86.5 (±17.6) | 87.8 (±18.7) | 0.808 |
| FVC a year after biopsy (mean ±SD) | 85.7 (±16.1) | 84.0 (±15.6) | 0.710 |
| FEV1/ FVC a year after biopsy (mean ±SD) | 106.8 (±8.2) | 109.4 (±9.0) | 0.306 |
| Extra-pulmonary involvement *, n (%) | 7 (17.5%) | 8 (21.6%) | 0.648 |
| Mortality, n (%) | 1 (2.5%) | 1 (2.7%) | 0.955 |
*Defined as damage to organs other than pulmonary damage (TLN and lung parenchyma)- neurosarcoidosis, cardiac sarcoidosis, dermal lesions, etc. Abbreviations: FEV1, Forced expiratory volume in one second. FVC, Forced vital capacity.